

Product Data Sheet

Product Name: Zocilurtatug pelitecan

Cat. No.: GC78805

Chemical Properties

Cas. No. 3058592-88-1

Formula

M.Wt

Solubility

Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure

Zocilurtatug pelitecan

Background

Zocilurtatug pelitecan (ZL-1310) is a blood-brain barrier-penetrating antibody-drug conjugate targeting DLL3. It consists of the antibody component Zocilurtatug and the toxin-linker molecule DL-01. Zocilurtatug pelitecan induces cell cycle arrest and apoptosis in tumor cells, and inhibits the growth of established human tumors in xenograft models. It can be used in research on extensive-stage small cell lung cancer (SCLC) and neuroendocrine tumors [1] [2].

In Vivo, ZL-1310 (administered intravenously) exhibits dose-dependent inhibition of tumor growth in

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

CDX and PDX mouse models of DLL3-positive small cell lung cancer, with significant intratumoral accumulation of the cytotoxic payload; additionally, it shows stable pharmacokinetic profiles and acceptable tolerability in GLP toxicology studies conducted in rats and non-human primates^{[1][2]}.

In Vitro, Zocilurtatug pelitecan (ZL-1310) binds specifically to DLL3 across species but not other Delta family members, and induces internalization, cell cycle arrest, and apoptosis in DLL3-expressing tumor cells^[1].

References:

- [1]. Lin, L. N., et al. (2024). 241P Development and characterization of a novel DLL3-targeting antibody drug conjugate (ADC) for the treatment of solid tumors. ESMo Open, 9.
- [2]. Dowlati, A., et al. (2026). A randomized, open-label, phase 3 study of ZL-1310, a DLL3 antibody-drug conjugate (ADC), compared to investigator's choice therapy in participants with relapsed small cell lung cancer (DLLEVATE).

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA